BCRX sinks 9% after competitor reports strong hereditary angioedema results
BioCryst Pharmaceuticals shares fell sharply Tuesday, dropping 9%. The selloff follows a competitor’s strong late-stage results in hereditary angioedema, the rare swelling disorder behind BioCryst’s main product.